Clin2
NCT06704204Possibly a fitNot yet recruiting

Injectable HIV treatment for people leaving prison

HIV

Part of Immune system & allergy, Infections, Mental health clinical trials.

This study offers a long-acting injectable HIV medication (cabotegravir/rilpivirine) to people with HIV who are about to be released from a Maryland prison. The goal is to make it easier to stay on treatment after returning to the community in Baltimore City.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
20 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You speak English.
  • You have HIV and are currently taking oral HIV medication.
  • Your HIV viral load has been undetectable (below 50 copies/mL) in the last 12 weeks.
  • You are expected to be released from a Maryland prison within 12 weeks to Baltimore City.
  • You are willing to switch from daily pills to an injection every 1-2 months at a community clinic.
  • You can provide informed consent.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06171919Recruiting
Legal help for people with HIV after incarceration

This study provides legal support to improve HIV care for people who have recently been released from jail or prison. It helps them stay in treatment and lower their viral load.

Orlando, Florida
NCT07103928Not yet recruiting
HIV partner notification study in prison

This study helps people recently diagnosed with HIV in prison inform their partners. If you have been sexually active or shared needles in the year before your current stay, this research may be for you.

Depok, West Java
NCT06316089Not yet recruiting
PrEP support for recently incarcerated men who inject drugs

This study tests a program to help men who recently left prison and use injectable drugs start and stick with PrEP, a daily pill that prevents HIV. It aims to improve health and connect them with care.

NCT06854029Not yet recruiting· Phase 4
Optimizing HIV prevention and opioid treatment in jail

This study tests whether a combination of buprenorphine (a medication for opioid addiction) and PrEP (a daily pill to prevent HIV) can help people who are leaving jail or prison stay healthy. It aims to reduce both opioid relapse and HIV risk during the transition back to the community.

Durham, North Carolina
NCT06507059Recruiting· Phase 3
Injectable HIV treatment trial for people with unsuppressed virus

This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.

Keelung
NCT06635421Not yet recruiting
Pharmacist-Given Long-Acting HIV Injections Study

This study looks at whether pharmacists can give you your long-acting HIV injections instead of a doctor, making it easier to get your medication. It might help you if you're already stable on these injections and want more convenience.

Hear when a new HIV trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.